 |
|
|
|
 |
|
|
| Article 1 to 10 out of 38 concerning Pharmexa A/S
|
-
Pharmexa appoints new Chief Executive Officer and implements further cost-saving measures
(06/27/2008)
Dr. Achim Kaufhold (50) becomes new Chief Executive Officer and succeeds Jakob Schmidt. The board of directors in Pharmexa intends to nominate Jakob Schmidt as a new board member for election at the next general assembly of the company. Pharmexa is ...
-
Pharmexa and Ichor Medical Systems enter into an agreement to co-develop multiple DNA vaccines delivered by electroporation
(03/12/2008)
Pharmexa and Ichor have entered into an agreement to co-develop multiple DNA vaccines to combat important diseases of high unmet medical need. It is well recognized that in vivo electroporation is a promising means of enhancing the potency of DNA ...
-
Pharmexa extends and updates license agreement with H. Lundbeck A/S
(12/18/2007)
Pharmexa and Lundbeck have entered into a new agreement, which is an extension of the original research and license agreement from April 2000, wherein H. Lundbeck received a global and exclusive license to PX106, a vaccine against Alzheimer's ...
-
New promising results published on Pharmexa's PADRE epitope in Alzheimer's vaccine
(11/23/2007)
A group of scientists from the Institute of Molecular Medicine at Huntington Beach (California) and the Institute of Brain Aging and Dementia at the University of California has published new pre-clinical data on an experimental second generation ...
-
New clinical results support telomerase vaccination in breast cancer
(11/06/2007)
A group of prominent scientists from the Abramson Cancer Center and the University of Pennsylvania School of Medicine has published new clinical data on vaccination with the telomerase peptide I540 in 19 metastatic breast cancer patients. The ...
-
Achim Kaufhold joins Pharmexa as Executive Vice President, CSO and CMO
(09/20/2007)
Professor Achim Kaufhold, M.D. (49) joins Pharmexa as Executive Vice President, Chief Scientific Officer (CSO) and Chief Medical Officer (CMO).Dr Kaufhold has spent more than 12 years in the biotech and pharmaceutical industry in senior management ...
-
Pharmexa again prevails against Geron in patent appeal
(09/04/2007)
In May 2004 the US biotech company Geron filed an opposition against Pharmexa's issued European patent (EP1093381) covering the telomerase vaccine GV1001. In 2005, the Opposition Division of the European Patent Office refused to grant Geron's ...
-
Pharmexa's Chief Commercial Officer resigns
(08/27/2007)
Chief Commercial Officer (CCO) Peter Nordkild has resigned his position in Pharmexa to accept the position as CEO in the Danish biotech company Egalet. Peter Nordkild's responsibilities will until further notice be taken over by Chief Executive ...
-
Pharmexa presents data from influenza program
(06/25/2007)
Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's ...
-
Pharmexa starts pivotal phase III trial in the United States
(05/07/2007)
The FDA has approved Pharmexas IND to start the PrimoVax trial in the United States. PrimoVax is a pivotal phase III trial testing the peptide vaccine GV1001 in patients with non-resectable pancreatic cancer. According to the plan the trial will ...
Additional information
Pharmexa A/S
Hørsholm, Denmark
Company
|
|
|
|
|
|
Top
